#1 Clinical Trials Search in Europe

Namodenoson

Namodenoson, also known as CF102, is an experimental drug currently being studied in clinical trials for its potential in treating various cancers and liver conditions. This article explores the ongoing research on Namodenoson, focusing on its use in advanced pancreatic cancer, non-alcoholic steatohepatitis (NASH), and advanced hepatocellular carcinoma (liver cancer) in patients with cirrhosis. These trials aim to evaluate the safety, efficacy, and potential benefits of Namodenoson in improving patient outcomes and quality of life.

Table of Contents

Introduction

Namodenoson, also known as CF102, is an experimental drug currently being studied for its potential to treat several serious medical conditions[1][2][3]. This article will provide an overview of what is currently known about Namodenoson based on ongoing clinical trials, including the conditions it may treat, how it works, and what patients can expect if they participate in a trial using this medication.

What is Namodenoson?

Namodenoson is a drug that belongs to a class of medications called Adenosine A3 Receptor (A3AR) agonists[3]. It is being developed as an oral medication, typically given as a capsule that patients take by mouth twice daily[1][2][3]. The drug is still in the experimental stages and is not yet approved for general use outside of clinical trials.

Conditions Treated with Namodenoson

Based on current clinical trials, Namodenoson is being studied for its potential to treat several serious conditions:

  • Advanced Pancreatic Cancer: A type of cancer that begins in the pancreas and has spread to other parts of the body[1].
  • Non-Alcoholic Steatohepatitis (NASH): A severe form of non-alcoholic fatty liver disease where fat accumulation in the liver leads to inflammation and liver cell damage[2].
  • Advanced Hepatocellular Carcinoma (HCC): The most common type of primary liver cancer, specifically in patients with a certain level of liver function impairment (Child-Pugh Class B7 cirrhosis)[3].

How Namodenoson Works

Namodenoson works by targeting and activating a specific protein in the body called the Adenosine A3 Receptor (A3AR)[3]. While the exact mechanisms are still being studied, researchers believe that by interacting with this receptor, Namodenoson may help to:

  • Slow down or stop the growth of cancer cells in pancreatic cancer and liver cancer
  • Reduce inflammation and fat accumulation in the liver for patients with NASH
  • Potentially improve overall liver function in patients with liver diseases

Current Clinical Trials

Namodenoson is currently being studied in several clinical trials:

  • Advanced Pancreatic Cancer Trial: This is a Phase 2 open-label study evaluating the safety and effectiveness of Namodenoson in patients with advanced pancreatic cancer[1].
  • NASH Trial: A Phase 2B randomized, double-blind, placebo-controlled study looking at the efficacy and safety of Namodenoson in treating non-alcoholic steatohepatitis[2].
  • Advanced Liver Cancer Trial: A Phase 3 randomized, double-blind, placebo-controlled study examining the efficacy and safety of Namodenoson in patients with advanced hepatocellular carcinoma and Child-Pugh Class B7 cirrhosis[3].

How Namodenoson is Administered

In the current clinical trials, Namodenoson is typically given as follows:

  • Oral capsules taken twice daily
  • The dose being studied is usually 25 mg every 12 hours
  • Treatment cycles are often 28 days long and may continue for several months or until disease progression or unacceptable side effects occur[1][2][3]

Potential Side Effects

As with any medication, Namodenoson may cause side effects. In the clinical trials, researchers are closely monitoring patients for any adverse events. The types, frequency, and severity of side effects are being carefully documented[1][3]. It’s important to note that not all potential side effects may be known at this stage of research.

Future Outlook

The results of these clinical trials will help determine the future of Namodenoson as a potential treatment for pancreatic cancer, NASH, and liver cancer. If the trials show positive results in terms of safety and efficacy, it could lead to further studies and potentially FDA approval for use in these conditions. However, it’s important to remember that drug development is a long and complex process, and not all drugs that show promise in clinical trials end up being approved for general use.

Frequently Asked Questions

1. Is Namodenoson currently available for patients outside of clinical trials?

No, Namodenoson is still an experimental drug and is only available to patients participating in clinical trials. It has not yet been approved by the FDA for general use.

2. How long do patients typically take Namodenoson in these trials?

The duration of treatment varies depending on the specific trial and the patient’s response. In some trials, patients may continue taking Namodenoson for several months or even up to a year, as long as they don’t experience disease progression or unacceptable side effects.

3. What should I do if I’m interested in participating in a Namodenoson clinical trial?

If you’re interested in participating in a clinical trial for Namodenoson, you should discuss this with your healthcare provider. They can help determine if you might be eligible for any ongoing trials and guide you through the process of potentially enrolling.

Glossary

  • Adenosine A3 Receptor (A3AR) agonist – A type of drug that activates the A3AR protein in the body, potentially leading to various therapeutic effects.
  • Hepatocellular Carcinoma (HCC) – The most common type of primary liver cancer, originating in the main type of liver cell (hepatocyte).
  • Non-Alcoholic Steatohepatitis (NASH) – A severe form of non-alcoholic fatty liver disease characterized by liver inflammation and damage caused by a buildup of fat in the liver.
  • Child-Pugh Class B7 cirrhosis – A specific classification of liver function impairment in patients with cirrhosis, indicating moderate liver dysfunction.
Condition Trial Phase Dosage Primary Outcomes
Advanced Pancreatic Cancer Phase 2 25 mg twice daily Safety, adverse events, ECOG Performance Status
Non-Alcoholic Steatohepatitis (NASH) Phase 2B 25 mg twice daily NAFLD activity score improvement, adverse events
Advanced Hepatocellular Carcinoma Phase 3 25 mg twice daily Overall Survival

Trial sources

  • [1]: https://clinicaltrials.gov/study/NCT06387342
  • [2]: https://clinicaltrials.gov/study/NCT04697810
  • [3]: https://clinicaltrials.gov/study/NCT05201404
Aspect Details
Drug Name Namodenoson (CF102)
Conditions Studied Advanced Pancreatic Cancer, Non-Alcoholic Steatohepatitis (NASH), Advanced Hepatocellular Carcinoma with Child-Pugh Class B7 Cirrhosis
Administration Oral capsule, 25 mg twice daily
Primary Outcomes Safety, Overall Survival, NAFLD Activity Score improvement
Secondary Outcomes Progression-Free Survival, Objective Response Rate, Changes in liver function tests
Other Measures Quality of Life, Pharmacokinetics, Biomarkers (CA 19-9, CEA, Pro-C3, ELF Score)
Trial Designs Phase 2 open-label (pancreatic cancer), Phase 2B randomized double-blind (NASH), Phase 3 randomized double-blind (hepatocellular carcinoma)
Duration Varies by trial: 36 weeks for NASH, up to 1 year for pancreatic cancer, and until disease progression for hepatocellular carcinoma

FAQ

  • What is Namodenoson and what conditions is it being studied for? Namodenoson, also known as CF102, is an experimental drug being studied in clinical trials for advanced pancreatic cancer, non-alcoholic steatohepatitis (NASH), and advanced hepatocellular carcinoma (liver cancer) in patients with cirrhosis. It is an Adenosine A3 Receptor (A3AR) agonist, which means it targets specific receptors in the body.
  • How is Namodenoson administered in these clinical trials? In the clinical trials, Namodenoson is administered orally as a capsule. The dosage is typically 25 mg taken twice daily, every 12 hours. The duration of treatment varies depending on the specific trial, ranging from 36 weeks to until disease progression or unacceptable side effects occur.
  • What are the main goals of these clinical trials involving Namodenoson? The main goals of these trials are to evaluate the safety, efficacy, and tolerability of Namodenoson. Researchers are looking at various outcomes, including overall survival, progression-free survival, objective response rate, and quality of life improvements. They are also monitoring for any adverse events and studying the drug's pharmacokinetics (how the body processes the drug).
  • How do researchers measure the effectiveness of Namodenoson in these trials? Researchers use various methods to measure the effectiveness of Namodenoson. These include regular tumor imaging (every 8 weeks in some trials), blood tests to measure biomarkers, liver biopsies (in the NASH trial), and quality of life questionnaires. They also track survival rates, disease progression, and changes in liver function tests.
  • Are there any side effects associated with Namodenoson in these trials? While specific side effects are not detailed in the provided information, all clinical trials closely monitor for adverse events. In these studies, researchers are assessing the incidence, severity, and nature of any treatment-emergent adverse events. The safety of Namodenoson is a primary focus in all the trials, with regular evaluations and reporting of any side effects.

Ongoing Clinical Trials on Namodenoson

  • Study of Namodenoson Treatment in Patients with Non-Alcoholic Steatohepatitis (NASH) and Liver Fibrosis

    Recruiting

    1
    Investigated drugs:
    Bulgaria Poland Romania

Glossary

  • Namodenoson: An experimental drug, also known as CF102, being studied for its potential in treating various cancers and liver conditions. It is an Adenosine A3 Receptor (A3AR) agonist.
  • Pancreatic Adenocarcinoma: A type of cancer that starts in the cells that line the ducts of the pancreas, which is an organ located behind the stomach that helps with digestion and regulating blood sugar.
  • Non-Alcoholic Steatohepatitis (NASH): A type of fatty liver disease not caused by alcohol consumption, characterized by inflammation and damage to liver cells, which can lead to scarring of the liver.
  • Hepatocellular Carcinoma: The most common type of primary liver cancer, which begins in the main type of liver cell (hepatocyte).
  • Cirrhosis: A late stage of scarring (fibrosis) of the liver caused by many forms of liver diseases and conditions, such as hepatitis and chronic alcoholism.
  • RECIST: Response Evaluation Criteria in Solid Tumors, a set of rules used to measure how well a cancer patient responds to treatment.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with the disease but it does not get worse.
  • Overall Survival (OS): The length of time from either the date of diagnosis or the start of treatment for a disease that patients are still alive.
  • Objective Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Pharmacokinetics: The study of how a drug moves through the body, including how it is absorbed, distributed, metabolized, and excreted.
  • Child-Pugh Class B7 Cirrhosis: A scoring system used to assess the prognosis of chronic liver disease, specifically cirrhosis. Class B7 indicates a moderate level of liver dysfunction.
  • EORTC QLQ-C30: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30, a tool used to assess the quality of life of cancer patients.